Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Charter Communications Inc (CHTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Charter Communications Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Charter Communications Inc trades at $157.69 (market cap $18.28B). The key difference: Charter Communications Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| BIO | CHTR | |
|---|---|---|
Market Cap | $9.39B | $18.28B |
Sector | Health | Media |
52-Week High | $354.54 | $282.74 |
52-Week Low | $241.71 | $123.31 |
Enterprise Value | $9.14B | $114.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Charter Communications (CHTR) trades at $152.57, down 3.09% on the day, with a bullish technical signal from moving averages but mixed oscillators. The stock shows low valuation multiples with a P/E of 3.97 and P/S of 0.36, supported by a 9.05% net income margin and strong operating cash flow of $16.08B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $10.66 versus $9.98 estimated, though revenue declined 1.7% year-over-year. News highlights debt refinancing activities and competitive pressures in broadband.
The outlook remains cautious due to subscriber losses and fiber competition, but the extreme valuation discount and aggressive buybacks offer potential upside. Risks include high debt leverage at $93.21B long-term and persistent industry headwinds. Analyst consensus is mixed with a $166.18 price target, suggesting 9% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
